Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment
Mov Disord Clin Pract
.
2018 Apr 15;5(3):255-258.
doi: 10.1002/mdc3.12611.
eCollection 2018 May-Jun.
Authors
Tom Foltynie
1
,
Dilan Athauda
1
Affiliation
1
National Hospital for Neurology & Neurosurgery, Queen Square London.
PMID:
30800701
PMCID:
PMC6336433
DOI:
10.1002/mdc3.12611
No abstract available
Keywords:
GLP‐1; MSA; Parkinson's disease; exenatide; repurposing.